Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002634308 | SCV003523236 | pathogenic | Catecholaminergic polymorphic ventricular tachycardia 1 | 2024-03-20 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 6 of the CASQ2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CASQ2 are known to be pathogenic (PMID: 12386154). This variant is present in population databases (rs753636068, gnomAD 0.0009%). Disruption of this splice site has been observed in individual(s) with catecholaminergic polymorphic ventricular tachycardia (PMID: 21618644). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 2202832). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005011096 | SCV005629255 | likely pathogenic | Catecholaminergic polymorphic ventricular tachycardia 2 | 2024-03-05 | criteria provided, single submitter | clinical testing |